Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Volunteer Human Challenge Model

NCT ID: NCT02371668

Last Updated: 2020-03-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 104 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-02-25
• Study Completion Date: 2018-11-30

Brief Summary

Background:

• Researchers want to see if a new drug reduces flu disease in people treated with this drug versus a placebo. The drug has an antibody that may help the immune system fight the flu. Placebo is only sugar and water. All participants will get the flu virus. They may or may not develop flu symptoms.

Objective:

• To see if the drug CR6261 reduces flu disease in people treated with this drug versus a placebo.

Eligibility:

• Healthy nonsmokers ages 18 45.

Design:

• Participants will be screened under a separate protocol.
• Participants must use contraception or abstinence for several weeks before and after the study. They must have no alcohol for 1 day before each visit. Any medicine must be approved by the study doctor until after follow-up.
• Participants will stay in a hospital isolation unit for at least 10 days.
• They will have:
• Medical history
• Physical exam
• Blood and urine tests
• Heart and lung test
• Tests for drugs and alcohol
• Throughout their stay, participants will:
• Be closely watched by a medical team
• Have nasal washes and swabs several times a day
• Participants will have the flu virus sprayed in each nostril.
• The next day, participants will get either study drug or placebo through a soft plastic tube placed in a vein by needle. It will take 2 hours. They will not know which they get.
• Participants can go home after 10 days if they test negative for the flu 2 days in a row.
• Participants will have daily questionnaires at home and 2 follow-up visits over 2 months.

Detailed Description

The high morbidity and mortality associated with both pandemic and seasonal influenza and the threat of new potentially pandemic strains emerging makes influenza an important infectious disease and public health problem. Mean annual estimates of influenza deaths due to seasonal influenza alone attributes up to 49,000 deaths in the US and 250,000 to 500,000 deaths in industrialized countries to influenza. Pandemics can have an even more devastating effect. Public health agencies must continue to be prepared by making attempts to reduce the public health impact of this important virus.

In the realm of influenza therapeutics, antiviral drugs are currently used to treat influenza infection in those who fail to be protected by current vaccines or those who do not receive a vaccine. Currently, only two classes of antivirals are FDA approved for the treatment of influenza A: neuraminidase inhibitors and matrix M2 channel blockers. Although these drugs have been shown to be effective in reducing influenza illness by 24-48 hours and reducing shedding in relatively healthy adults, as with vaccination, they have had limited effectiveness in high risk groups and those who have severe or complicated influenza infections. In addition, antiviral resistance has become very common in human influenza A viruses, as currently circulating H1N1 and H3N2 strains are resistant to the adamantane M2 channel blockers and many cases of neuraminidase inhibitor resistance have also been reported with strains of both subtypes. This resistance can develop quickly and in most cases only requires a single amino acid change. Given these significant issues with currently available treatments, novel therapies for influenza are clearly needed.

Live virus challenge studies have played a pivotal role in developing influenza therapeutics in the past, and they will be instrumental in the future. No novel therapeutic or prophylactic agent has been FDA-approved since the last influenza challenge studies ceased over a decade ago. In collaboration with the Crucell Vaccine Institute (part of Crucell which is in the Janssen family of Pharmaceutical Companies of Johnson & Johnson) this protocol will evaluate mAb CR6261 for possible therapeutic value. Unlike the current antivirals that are compounds which interfere with some portion of the viral replicative cycle, this agent is a mAb that targets the stem of HA, neutralizing the virus by stabilizing the pre-fusion state and preventing the pH-dependent fusion of viral and cellular membranes. Pre-clinical data suggest that this mAb has good cross-protective efficacy with a variety of HA subtypes unlike current vaccines, making it potentially effective in the event of an emerging influenza virus outbreak with a novel HA subtype. In addition, the conserved nature of the HA stem region suggests that amino acid changes conferring resistance are much less likely. We will effort to demonstrate that CR6261 leads to improved outcomes compared with placebo with respect to the AUC of virus shedding as determined by qPCR in NP swabs in all treated subjects.

Conditions

H1N1 Influenza Healthy Volunteers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: DOUBLE

Study Groups

Placebo

Placebo, 5% dextrose (D-glucose) water

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: BIOLOGICAL

Administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).

CR6261

CR6261, Investigational monoclonal antibody against influenza A viruses

Group Type: EXPERIMENTAL

CR6261

Intervention Type: BIOLOGICAL

50 mg/kg administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).

Interventions

CR6261

50 mg/kg administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).

Intervention Type: BIOLOGICAL

Placebo

Administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Greater than or equal to 18 and less than or equal to 45 years of age.

2. Non-smoker.

3. Willingness to remain in isolation for the duration of viral shedding (at a minimum 10 days) and to comply with all study requirements.

5. A female participant is eligible for this study if she is not pregnant or breast feeding and 1 of the following:

• Of nonchildbearing potential (i.e., women who have had a hysterectomy or tubal ligation or are postmenopausal, as defined by no menses in greater than or equal to 1 year).
• Of childbearing potential but agrees to practice effective contraception or abstinence for 4 weeks prior to and 8 weeks after administration of the influenza challenge virus. Acceptable methods of contraception include a male partner who is sterile and is the sole sexual partner of the female participant or a male partner who uses a condom with spermicide plus 1 or more of the following: 1) implants of levonorgestrel; 2) injectable progestogen; 3) an intrauterine device with a documented failure rate of <1%; 4) oral contraceptives; and 5) double barrier method including diaphragm.

6. Willing to have samples stored for future research.

7. Prechallenge serum HAI titer against the challenge virus less than or equal to 1:10 within 60 days of admission for the study.

8. HIV uninfected confirmed by testing within 60 days of admission for the study.

9. Agrees to abstain from alcohol intake 24 hours before admission on Day -1, during the inpatient period of the study, and 24 hours prior to all other outpatient clinic visits.

10. Agrees to not use over-the-counter medications (including aspirin, decongestants, antihistamines, and other NSAIDs), and herbal medication (including, but not limited to, herbal tea, St. John s Wort), within 14 days prior to study drug administration through the final follow-up visit, unless approved by the investigator.

Exclusion Criteria

1. Presence of self-reported or medically documented significant medical condition including but not limited to:

1. Chronic pulmonary disease (e.g., asthma, emphysema).

2. Chronic cardiovascular disease (e.g., cardiomyopathy, congestive heart failure, cardiac surgery, ischemic heart disease, known anatomic defects).

3. Chronic medical conditions requiring close medical follow-up or hospitalization during the past 5 years (e.g., insulin dependent diabetes mellitus, renal dysfunction, hemoglobinopathies).

4. Immunosuppression or ongoing malignancy.

5. Neurological and neurodevelopmental conditions (e.g., cerebral palsy, epilepsy, stroke, seizures).

6. Postinfectious or postvaccine neurological sequelae.

7. Hyperlipidemia requiring medical therapy per current American College of Cardiology (ACC) and American Heart Association (AHA) guidelines published in 2013.

2. Have close or household (i.e., share the same apartment or house) high-risk contacts including but not limited to:

1. Persons greater than or equal to 65 years of age.

2. Children less than or equal to 5 years of age.

3. Residents of nursing homes.

4. Persons of any age with significant chronic medical conditions such as:

• Chronic pulmonary disease (e.g., severe asthma, COPD).
• Chronic cardiovascular disease (e.g., cardiomyopathy, congestive heart failure, cardiac surgery, ischemic heart disease, known anatomic defects).
• Contacts who required medical follow-up or hospitalization during the past 5 years because of chronic metabolic disease (e.g., insulin dependent diabetes mellitus, renal dysfunction, hemoglobinopathies).
• Immunosuppression or cancer.
• Neurological and neurodevelopmental conditions (e.g., cerebral palsy, epilepsy, stroke, seizures).
• Individuals who are receiving long-term aspirin therapy.
• Women who are pregnant or who are trying to become pregnant.

3. Positive serology for hepatitis C virus antibody or hepatitis B surface antigen.

4. Individual with body mass index (BMI) greater than or equal to 18 and greater than or equal to 35 or weight > 114kg.

5. Acute illness within 7 days of admission and inoculation with the challenge virus (Day -1).

6. Complete blood count (CBC) with differential outside of the NIH Department of Laboratory Medicine (DLM) normal reference range and deemed clinically significant by the PI.

7. Chemistries in the acute care, mineral, and/or hepatic panels, and/or any of the following: lactate dehydrogenase, uric acid, creatine kinase, and total protein outside of the NIH DLM normal reference range and deemed clinically significant by the PI.

8. Amylase or Lipase outside of the NIH DLM normal reference range and deemed clinically significant by the PI.

9. Urinalysis outside of the NIH DLM normal reference range and deemed clinically significant by the PI.

10. Clinically significant abnormality as deemed by the PI on electrocardiogram.

11. Clinically significant abnormality as deemed by the PI on echocardiographic (ECHO) testing.

12. Clinically significant abnormality as deemed by the PI on the Pulmonary Function Test (PFT).

13. Known allergy to treatments for influenza (including but not limited to oseltamivir, nonsteroidals).

14. Known allergy to 2 or more classes of antibiotics (e.g., penicillins, cephalosporins, fluoroquinolones, or glycopeptides).

15. Receipt of blood or blood products (including immunoglobulins) within 3 months prior to enrollment.

16. Receipt of any unlicensed drug within 3 months or 5.5 half-lives (whichever is greater) prior to enrollment.

17. Receipt of any non-influenza-related unlicensed vaccine within 6 months prior to enrollment.

18. Self-reported or known history of current alcoholism or drug abuse, or positive urine/serum test for drugs of abuse and/or ethanol (i.e., amphetamines, cocaine, benzodiazepines, opiates, or metabolites, but not tetrahydrocannabinol (THC) or metabolites).

19. Self-reported or known history of psychiatric or psychological issues deemed by the PI to be a contraindication to protocol participation.

19. Known close contact with anyone known to have influenza in the past 7 days.

21. Known or suspected hypersensitivity to CR6261 or its excipients (sucrose, L-histidine, L-histidine monohydrochloride, polysorbate 20).

22. History of a previous severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis.

23. Drinks more than 1200 mL (or 5 cups of 240 mL per cup) of tea/coffee/cocoa/cola or other caffeinated beverage per day more than 1 day per week in the 2 weeks before screening.

24. Any condition or event that, in the judgment of the PI, is a contraindication to protocol participation or impairs the volunteer s ability to give informed consent.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Matthew J Memoli, M.D.

Role: PRINCIPAL_INVESTIGATOR

National Institute of Allergy and Infectious Diseases (NIAID)

Locations

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, United States

Countries

United States

References

Han A, Czajkowski L, Rosas LA, Cervantes-Medina A, Xiao Y, Gouzoulis M, Lumbard K, Hunsberger S, Reed S, Athota R, Baus HA, Lwin A, Sadoff J, Taubenberger JK, Memoli MJ. Safety and Efficacy of CR6261 in an Influenza A H1N1 Healthy Human Challenge Model. Clin Infect Dis. 2021 Dec 6;73(11):e4260-e4268. doi: 10.1093/cid/ciaa1725.

Reference Type: DERIVED

PMID: 33211860 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

15-I-0069

Identifier Type: OTHER

Identifier Source: secondary_id

150069

Identifier Type: -

Identifier Source: org_study_id